Back

Polymer-free amphilimus-eluting stents vs. biodegradable-polymer everolimus-eluting stents in all-comers undergoing pci: 2-year results of the PARTHENOPE trial

19 February 2026 (13:30 - 14:30)
Organised by: Logo
Congress Presentation Part of: Personalised PCI: special populations, innovative devices and tailored therapy Revascularisation EAPCI Premium Access EAPCI Summit 2026 European Association of Percutaneous Cardiovascular Interventions (EAPCI)

About the speaker

Photo
Associate Professor Raffaele Piccolo

University of Naples Federico II, Naples (Italy)

6 More presentations in this session

Presentation thumbnail
Cardio-kidney-metabolic phenotypes determine residual cardiovascular risk after acute coronary syndromes
Miss Y. Wang (Zurich, CH)
Abstract Slides
Presentation thumbnail
Impact of cardio-oncology services on care and outcomes of STEMI patients with active cancer
Doctor M. Dafaalla (Stoke-on-Trent, GB)
Abstract Slides
Presentation thumbnail
Impact of sex on residual angina after percutaneous coronary interventions
Doctor D. Munhoz (Aalst, BE)
Abstract Slides
Presentation thumbnail
What makes it stentless? Development and internal validation of bailout risk score in DCB-only PCI
Doctor L. Iossa (Mercogliano, IT)
Abstract Slides
Presentation thumbnail
Long-term outcomes following drug-coated balloons versus thin-strut drug-eluting stents for treatment of in-stent restenosis in acute coronary syndrome (ACS dragon-registry)
Professor R. Januszek (Krakow, PL)
Abstract Slides

Access the full session

Session thumbnail
Personalised PCI: special populations, innovative devices and tailored therapy

The Event

Event poster

EAPCI Summit 2026

19 February 2026 13:30 CET

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources